腰痹通胶囊联合美洛昔康治疗以炎性背痛为特点的强直性脊柱炎临床研究

目的:观察腰痹通胶囊联合美洛昔康治疗以炎性背痛为特点的强直性脊柱炎(AS)的临床疗效。方法:选取38例以炎性背痛为特点的AS患者,采用抽签法随机分为对照组和观察组各19例。对照组单纯给予美洛昔康治疗,观察组给予腰痹通胶囊联合美洛昔康治疗,2组均治疗4周。治疗后对比2组临床疗效,观察患者Bath强直性脊柱炎疾病活动性指数(BASDAI)、Bath强直性脊柱炎功能指数(BASFI)、晨僵时间及实验室指标的改善情况,记录不良反应发生情况。结果:观察组有效率84.21%,高于对照组的52.63%(P<0.05)。治疗后,2组BASDAI、BASFI均较治疗前降低(P<0.05,P<0.01),晨僵时间均较治疗前缩短(P<0.01);观察组BASDAI、BASFI均低于对照组(P<0.01),晨僵时间短于对照组(P<0.01)。治疗后,2组红细胞沉降率(ESR)、C-反应蛋白(CRP)水平均较治疗前降低(P<0.01);观察组ESR、CRP水平均低于对照组(P<0.05)。2组治疗过程中均未见严重不良反应发生。结论:腰痹通胶囊联合美洛昔康对以炎性背痛为特点的AS患者有较好的治疗作用。

Clinical Study on Yaobitong Capsules Combined with Meloxicam for Ankylosing Spondylitis Characterized by Inflammatory Back Pain

Objective: To observe the clinical effect of Yaobitong capsules combined with meloxicam for ankylosing spondylitis(AS) characterized by inflammatory back pain. Methods: A total of 38 cases of AS patients characterized by inflammatory back pain were selected and randomly divided into the control group and the observation group, 19 cases in each group. The control group was simply treated with meloxicam,and the observation group was additionally treated with Yaobitong capsules based on the treatment of the control group. Both groups were treated for four weeks. The clinical effect in the two groups was compared. The improvement of the Bath Ankylosing Spondylitis Disease Activity Index(BASDAI),the Bath Ankylosing Spondylitis Functional Index(BASFI),the duration of morning stiffness and laboratory indexes was observed.The incidence of adverse reactions was recorded. Results:The effective rate was 84.21% in the observation group,higher than that of 52.63% in the control group(P < 0.05). After treatment,the BASDAI and BASFI in the two groups were decreased when compared with those before treatment(P < 0.05,P < 0.01),and the duration of morning stiffness was shortened when compared with that before treatment(P < 0.01);the BASDAI and BASFI in the observation group were lower than those in the control group(P < 0.01), and the duration of morning stiffness was shorter than that in the control group(P < 0.01). After treatment,the levels of erythrocyte sedimentation rate(ESR) and C-reactive protein(CRP) in the two groups were decreased when compared with those before treatment(P < 0.01);the above two levels in the observation group were lower than those in the control group(P < 0.05). There was no severe adverse reaction during the treatment in the two groups. Conclusion:The therapy of Yaobitong capsules combined with meloxicam has better curative effect in treating AS characterized by inflammatory back pain.